CellaVision announces new reporting date for the 2010 January - March interim report
The Board of CellaVision AB (publ) has decided to publish the January - March 2010 Interim Report on Friday, April 23, 2010 instead of, as previously communicated, Thursday, April 29, 2010. Early publication allows CellaVision to better prepare for its planned listing on NASDAQ OMX, Small Cap.
For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 708 33 77 82. E-mail: email@example.com
Johan Wennerholm, CFO, CellaVision AB
Phone: 46 708 33 81 68. E-mail: firstname.lastname@example.org
CellaVision AB develops, markets, and sells market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.
The company headquarters are in Lund, Sweden. The company also has subsidiaries in the US, Canada and Japan. For more information, please visit www.cellavision.com.
CellaVision's share is listed on First North Premier at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.